Medtronic wins CE mark for OmniaSecure defibrillation lead
The company designed the lead to have the safety benefits of small-diameter devices without sacrificing durability.
Medtronic wins CE mark for OmniaSecure defibrillation lead Read More »
Uncategorized
PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting Disease
PepGen’s lead candidate for myotonic dystrophy type 1 barely beat the placebo in a Phase 2 trial in terms of fixing incorrect gene splicing, but the biotech attributed the poor result to an outlier.
PepGen Loses Half of Share Price on Mixed Data in Rare Muscle-Wasting Disease Read More »
Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy
In addition to delivering two approved medicines to Biogen’s portfolio, the acquisition of Apellis Pharmaceuticals will support the future launch of the pharma’s own kidney disease asset, currently in multiple Phase 3 trials.
Biogen Secures ‘Running Start’ in Kidney Disease With $5.6B Apellis Buy Read More »
Lilly Wakes Up Sleep Market With $6.3B Centessa Buy To Challenge Takeda
In the buyout, Eli Lilly picks up Centessa Pharmaceuticals’ lead asset cleminorexton, which could go toe-to-toe with Takeda’s oveporexton, currently under FDA review with a decision expected in the third quarter.
Lilly Wakes Up Sleep Market With $6.3B Centessa Buy To Challenge Takeda Read More »
Merck’s Cholesterol Pill Delivers ‘Antibody-Like Efficacy’ After Earning FDA Voucher
Merck is eyeing a quick review for its lipid-lowering drug candidate enlicitide, which in December was awarded a Commissioner’s National Priority Voucher.
Merck’s Cholesterol Pill Delivers ‘Antibody-Like Efficacy’ After Earning FDA Voucher Read More »
Viridian Turns Red as Thyroid Eye Disease Data Disappoint
Despite hitting its primary endpoint, Viridian’s thyroid eye disease antibody failed to ease eye bulging to the degree that analysts had been hoping for, and the biotech’s stock price fell by one-third.
Viridian Turns Red as Thyroid Eye Disease Data Disappoint Read More »
AAD 2026: Sanofi, Incyte, Roivant and Alumis Make Headway Into Skin Diseases
Presentations at the 2026 meeting of the American Academy of Dermatology not only demonstrate the therapeutic potential of next-generation skin drugs but also shed light on how they might fare on the market.
AAD 2026: Sanofi, Incyte, Roivant and Alumis Make Headway Into Skin Diseases Read More »
Nuevos materiales para células solares
Cada hora, la Tierra recibe del Sol una cantidad de energía comparable al consumo energético mundial de todo un año. El desarrollo de materiales bidimensionales hará posible el uso de cualquier superficie para absorber esta energía. Desde hace unos años, se …
Las mitocondrias como pieza clave en una enfermedad rara que provoca microcefalia
Las células humanas tienen dos copias de cada cromosoma y este equilibrio es esencial para que los genes se expresen en las proporciones adecuadas y las células funcionen correctamente. Cuando durante la división celular se producen errores y el número de cromosomas de la …
Las mitocondrias como pieza clave en una enfermedad rara que provoca microcefalia Read More »
Inteligencia artificial que se amolda a cada persona
Aunque las inteligencias artificiales del tipo de ChatGPT son expertas en responder innumerables preguntas, a menudo permanecen ajenas a la personalidad del usuario, a sus hábitos cotidianos e incluso a los contextos conversacionales previos. Por ello, el uso de inteligencia artificial, a pes …
Inteligencia artificial que se amolda a cada persona Read More »